Campath Related Published Studies
Well-designed clinical trials related to Campath (Alemtuzumab)
Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. [2009.02]
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). [2009.01]
Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up. [2008.09]
Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. [2008.07]
Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. [2008.07]
A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. [2008.03]
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. [2008.02.15]
FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. [2008.02]
A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. [2008.01]
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. [2007.12.10]
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. [2007.10.27]
Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. [2007.06.15]
Well-designed clinical trials possibly related to Campath (Alemtuzumab)
Nonsystemic vasculitic neuropathy: update on diagnosis, classification, pathogenesis, and treatment. [2009]
Monoclonal antibodies in the therapy of multiple sclerosis: an overview. [2008.12]
Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. [2008]
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. [2007.04.15]
Other research related to Campath (Alemtuzumab)
A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. [2009.12]
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. [2009.08.20]
Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. [2009.08]
Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis. [2009.07.20]
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). [2009.07]
Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. [2009.07]
[Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics] [2009.06]
Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag'). [2009.06]
Impact of induction therapy on bacterial infections and long-term outcome in adult intestinal and multivisceral transplantation: a comparison of two different induction protocols: daclizumab vs. alemtuzumab. [2009.06]
Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. [2009.06]
Alemtuzumab and liver transplantation: a review. [2009.06]
Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. [2009.05]
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. [2009.05]
Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. [2009.05]
Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. [2009.04.15]
Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation. [2009.04]
Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature. [2009.04]
Other possibly related research studies
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. [2009.09.12]
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. [2009.09.24]
[Monoclonal antibodies in neurology] [2009.05]
[Monoclonal antibodies in renal transplantation] [2009.05]
[Monoclonal antibodies in hematology in 2009] [2009.05]
Pentostatin treatment combinations in chronic lymphocytic leukemia. [2009.06]
Treating MS: getting to know the two birds in the bush. [2009.07]
Molecularly targeted therapies for dysimmune neuropathies. [2009.07]
Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning. [2009.06]
Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. [2009]
FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. [2009]
Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. [2009.06]
Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. [2009.05]
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. [2009.07.30]
Treatment of fludarabine-refractory chronic lymphocytic leukemia. [2009.07.01]
The role of stem cell transplantation in the management of chronic lymphocytic leukaemia. [2009.06]
Targeted therapy for chronic lymphocytic leukemia. [2009.01]
Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. [2009.04]
|
